Dosing regimen for a selective S1P1 receptor agonist
US12336980B2 · kind B2 · utility
0Cited by
19References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 13, 2022 |
| Grant date | Jun 24, 2025 |
| Priority date | — |
| Expiry date | Oct 13, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimmo)-3-o-tolyl-thiazolidin-4-one.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.